Enhance your lead candidate properties for early decision-making

1. EARLY METABOLITE SCREENING SERVICES
ENHANCE YOUR LEAD
CANDIDATE PROPERTIES
FOR EARLY DECISION-MAKING
Understanding the biotransformation of your compounds during lead optimization enhances
your lead candidate’s properties and enables you to make informed decisions early, preventing
costly development delays.
WHAT YOU GET: RAPID INFORMATION.
▶ Gain early comparative, cross-species information to support MIST, ICH M3 and EMA/FDA
DDI guidelines, including correct selection of preclinical tox species
▶ Make targeted modifications to alter clearance properties
▶ Assist in the risk assessment of drug-drug interactions
▶ Reduce reactive metabolites
▶ Identify potentially unique or disproportionate human metabolites early
STANDARIZED STUDY DESIGNS, TAILORED TO YOU.
Receive tailored study designs and documentation, based on your specific requirements. Our
team partners with you to help understand your needs and expectations.
▶ In vitro test systems:
– Microsomes and Hepatocytes
(S9 fraction and Cytosol on request)
– Up to 2 species
▶ Up to 5 test compounds
▶ Standardized master protocols
▶ Excel or abbreviated letter style reports
▶ Draft report within 10 days of
compound delivery
▶ Structural characterization of top 3
metabolites
▶ In vitro test systems:
– Microsomes and Hepatocytes
(S9 fraction and Cytosol on request)
– Up to 5 species
▶ In vivo test systems:
– Plasma and Urine
(faeces, bile and tissues on request)
▶ Up to 3 test compounds
▶ Standardized master protocols
▶ Abbreviated but comprehensive
template reports
▶ Draft report within 15 days of compound or
sample delivery
▶ Identification of metabolites 1% total peak
area response by accurate mass
▶ Structural characterization of top 10
metabolites
LEAD OPTIMIZATION THROUGH TO CANDIDATE SELECTION

2. GLOBAL CAPACITY. GLOBAL PROCEDURES.
GLOBAL DOCUMENTATION.
Enjoy the same customer experience and high-quality data across the globe with dedicated
metabolite identification facilities in Madison, Wisconsin, US and Harrogate, UK.
EXPERIENCED SCIENTIFIC TEAM.
▶ Work directly with our experienced and expanding scientific team:
– 10+ experienced Met ID scientists
– 5+ specialized study directors, averaging more than 10 years of industry experience
STATE-OF-THE-ART INSTRUMENTATION PLATFORMS.
Give your compounds the best chance of success, utilizing our intelligent software
and platforms.
▶ LC-MS PLATFORMS
We use high-resolution liquid
chromatography-mass spectrometry (LC-
MS) platforms globally. Models include
Waters XevoTM
G2-S QTof, Waters VionTM
IMS QTof and Thermo Q ExactiveTM
▶ INTELLIGENT SOFTWARE
Intelligent (MS) software speeds up
metabolite detection and interpretation.
▶ ION MOBILITY
Ion Mobility technology provides an
additional degree of separation to (LC) and
accurate mass. It reduces ambiguity of
metabolite assignment, allows better use
of data independent analysis, produces
cleaner spectra and cuts down on structural
characterization time.
GET STARTED TODAY. www.covance.com/earlymetid
Covance Inc., headquartered in Princeton, NJ, USA is the drug development business of Laboratory
Corporation of America Holdings (LabCorp). COVANCE is a registered trademark and the
marketing name for Covance Inc. and its subsidiaries around the world.
The Americas + 1.888.COVANCE (+1.888.268.2623) + 1.609.452.4440
Europe / Africa + 00.800.2682.2682 +44.1423.500888
Asia Pacific + 800.6568.3000 +65.6.5686588
© Copyright 2018 Covance Inc. SSSAMLO002-1018